GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation ...

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...

MISSISSAUGA, ON, May 26, 2025 /CNW/ - GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance ...